Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

The conversation is about using 1mg finasteride and 5% topical minoxidil for hair loss, along with a dermaroller, Alpecin caffeine shampoo, and Nizoral shampoo. Users express optimism about the potential improvement in hair density.

The user is happy with hair growth progress after using minoxidil foam and 1mg finasteride for over six months, despite initial scalp itching. They are considering switching to oral minoxidil for faster growth and are concerned about maintaining consistency with the foam application.

The user is undergoing Mesotherapy and Low-Level Laser Therapy for hair loss, with plans for multiple sessions. They are also using oral finasteride, topical minoxidil, dutasteride, and hair fibers.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The conversation discusses hair regrowth progress using Minoxidil, finasteride, and RU58841. It highlights the transformation of vellus hairs into terminal hairs in a Norwood 6 frontal area.

The user experienced significant hair regrowth using finasteride, minoxidil, and a 4,000-graft hair transplant performed by Dr. Nader in Reynosa, Mexico. The results were natural-looking, and the user plans a second transplant for additional density if needed.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The user experienced significant hair regrowth in the temple area after using 1mg finasteride daily for over a year, with no side effects. The user did not use minoxidil or microneedling and started experiencing hair loss at age 16.

The user shared progress pictures after 5 months of using 1mg finasteride, weekly 1.5mm microneedling, and daily 2mg copper peptide injections. They discussed their hair loss treatment and results.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

The user has been using topical minoxidil (5%) for two years and kx826/pyrilutamide for one year, after experiencing side effects from finasteride. They report positive results from the combination of minoxidil and kx826 in combating hair loss.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

The conversation is about using RF (radiofrequency) and microneedling to increase hair density. The user plans to shave their head and apply these treatments regularly, hoping for improved results.

The user experienced significant hair regrowth using 1mg finasteride and 2.5mg oral minoxidil, improving from NW5-6 to NW3-4 in three months. They plan to get a hair transplant in February and reported no side effects except increased body hair growth.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.

KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.

Polygonum multiflorum, also known as Fo-ti or He Shou Wu, is discussed as a potential treatment for hair loss. Users are interested in its effectiveness and dosage.

Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.

A woman with androgenetic alopecia uses Dutasteride and Bicalutamide but feels devastated due to increased sensitivity to DHT. She considers wigs, Minoxidil, and seeks advice on options like spironolactone, hair transplants, and therapy.

Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.

The conversation discusses using CB0301/Clascoterone as a potential treatment for hair loss, especially for those experiencing side effects from finasteride and dutasteride. The user currently uses oral minoxidil and considers combining it with other treatments like kx826, DHT blocker supplements, and 2% Nizoral shampoo.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Breezula (clascoterone) initially performed better than finasteride for hair loss but then effectiveness decreased almost back to baseline after 6 months, raising questions about its strength.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

A user shared their 11-month experience using a 272 diode red light hat for hair loss, noting decent results despite inconsistent use and no medication. Another user suggested that real treatment like minoxidil or finasteride is necessary for long-term hair maintenance.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.